Stock IMMX IMMIX BIOPHARMA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Immix Biopharma, Inc.

Equities

IMMX

US45258H1068

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-30 pm EDT 		5-day change 1st Jan Change
2.17 USD +2.36% Intraday chart for Immix Biopharma, Inc. -5.65% -68.64%
Apr. 29 Immix Biopharma Gets Orphan Drug Label in Europe For Multiple Myeloma Treatment MT
Apr. 18 Immix Biopharma on Track to Dose First Patients with AL Amyloidosis Therapy by Mid-Year MT

Evolution of the average Target Price on Immix Biopharma, Inc.

Price target over the last 5 years

History of analyst recommendation changes

88.4fGS52oS8U03sLdF2PhwzfcKILQbFlzjtSNpMhNg_Gk.t8L1s1pKgg5w8c0cqbQH-oNbZYRESQyL7RpdSng1qAHMoKLePXy8G1b71A~b55e67752b655bf8b647ee3d18f5f6e7

Analyst Recommendations on Immix Biopharma, Inc.

Immix Biopharma Inc. Announces 72-Patient NXC-201 Clinical Data at the IMS 20th Annual Meeting, 95% Overall Response Rate in Multiple Myeloma CI
Immix Biopharma Unit Says NXC-201 Shows 100% Overall Response Rate in Light Chain Amyloidosis Study MT
Roth MKM Initiates Immix Biopharma to Buy Rating With $14 Price Target MT
Immix Unit Says AL Amyloidosis Drug Candidate Showed 100% Complete Response Rate in Clinical Study MT
Immix Biopharma Says Cancer Drug IMX-110 Showed Higher Survival Rate Versus Johnson & Johnson Unit's Trabectedin in Mice Study MT
Immix Biopharma Says IMX-110 Candidate Elicits 50% Response Rate in Soft Tissue Sarcoma Study in Mice MT
Immix Biopharma, Inc IMX-110 Produces 50% Positive Response Rate in First-Line-Therapy-Resistant Cancer, Surpassing the Standard of Care in Mice Study CI
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
2.17 USD
Average target price
14 USD
Spread / Average Target
+545.16%
High Price Target
14 USD
Spread / Highest target
+545.16%
Low Price Target
14 USD
Spread / Lowest Target
+545.16%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Immix Biopharma, Inc.

Roth MKM

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. IMMX Stock
  4. Consensus Immix Biopharma, Inc.